conivaptan has been researched along with Diabetes Insipidus, Neurogenic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avila-Blanco, ME; Calvillo-Robedo, A; González-Blas, D; Muñoz-Ortega, MH; Navarro-Gonzalez, YD; Quintanar-Stephano, A; Valdez-Urias, F; Ventura-Juarez, J | 1 |
1 other study(ies) available for conivaptan and Diabetes Insipidus, Neurogenic
| Article | Year |
|---|---|
Arginine vasopressin deficiency and conivaptan (a V1a-V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis.
Topics: Anastomosis, Surgical; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine; Arginine Vasopressin; Cricetinae; Diabetes Insipidus, Neurogenic; Liver Cirrhosis; Rats; Receptors, Vasopressin | 2023 |